TY - JOUR
T1 - Up-regulation of telomerase activity in human pancreatic cancer cells after exposure to etoposide
AU - Sato, N.
AU - Mizumoto, K.
AU - Kusumoto, M.
AU - Nishio, S.
AU - Maehara, N.
AU - Urashima, T.
AU - Ogawa, T.
AU - Tanaka, M.
PY - 2000
Y1 - 2000
N2 - Telomerase plays a critical role in the development of cellular immortality and oncogenesis. Activation of telomerase occurs in a majority of human malignant tumours, and the relation between telomerase and vulnerability to drug-mediated apoptosis remains unclear. In this study, we demonstrate, for the first time, up-regulation of telomerase activity in human pancreatic cancer cells treated with etoposide, a topoisomerase II inhibitor. Exposure of MIA PaCa-2 cells to etoposide at various concentrations (1-30 μM) resulted in two- to threefold increases in telomerase activity. Up-regulation was detectable 24 h after drug exposure and was accompanied by enhanced expression of mRNA of the human telomerase reverse transcriptase. Telomerase activation was also observed in AsPC-1 and PANC-1 cells but not in KP-3 and KP-1N cells. Furthermore, we found a negative correlation between increased telomerase activity and the percentage of dead cells after etoposide treatment. These findings suggest the existence of an anti-apoptotic pathway through which telomerase is up-regulated in response to DNA damage. This telomerase activation pathway may be one of the mechanisms responsible for the development of etoposide resistance in certain pancreatic cancer cells. (C) 2000 Cancer Research Campaign.
AB - Telomerase plays a critical role in the development of cellular immortality and oncogenesis. Activation of telomerase occurs in a majority of human malignant tumours, and the relation between telomerase and vulnerability to drug-mediated apoptosis remains unclear. In this study, we demonstrate, for the first time, up-regulation of telomerase activity in human pancreatic cancer cells treated with etoposide, a topoisomerase II inhibitor. Exposure of MIA PaCa-2 cells to etoposide at various concentrations (1-30 μM) resulted in two- to threefold increases in telomerase activity. Up-regulation was detectable 24 h after drug exposure and was accompanied by enhanced expression of mRNA of the human telomerase reverse transcriptase. Telomerase activation was also observed in AsPC-1 and PANC-1 cells but not in KP-3 and KP-1N cells. Furthermore, we found a negative correlation between increased telomerase activity and the percentage of dead cells after etoposide treatment. These findings suggest the existence of an anti-apoptotic pathway through which telomerase is up-regulated in response to DNA damage. This telomerase activation pathway may be one of the mechanisms responsible for the development of etoposide resistance in certain pancreatic cancer cells. (C) 2000 Cancer Research Campaign.
UR - http://www.scopus.com/inward/record.url?scp=0034027053&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034027053&partnerID=8YFLogxK
U2 - 10.1054/bjoc.2000.1117
DO - 10.1054/bjoc.2000.1117
M3 - Article
C2 - 10839297
AN - SCOPUS:0034027053
SN - 0007-0920
VL - 82
SP - 1819
EP - 1826
JO - British Journal of Cancer
JF - British Journal of Cancer
IS - 11
ER -